TIANJIN Pharmaceutical Da Ren Tang Group Corp on Friday (Sep 9) said it was subscribing to up to 5.4 million new shares in NewScen Coast Bio-Pharmaceutical, a pharmaceutical manufacturing company based in China, for up to 43.2 million yuan (S$8.7 million) in cash.

LIM & TAN Securities has initiated coverage on dual-listed healthcare and biopharmaceutical company Tianjin Pharmaceutical Da Ren Tang (TDRT) with a “buy” and a target price of US$1.60 — representing a price-earnings ratio of 9.69 times, which is nearly half of its peers’ ave...

LIM & TAN Securities has initiated coverage on dual-listed healthcare and biopharmaceutical company Tianjin Pharmaceutical Da Ren Tang (TDRT) with a “buy” and a target price of US$1.60 — representing a price-earnings ratio of 9.69 times, which is nearly half of its peers’ ave...

Tianjin Zhong Xin Pharmaceutical Group says Jinhushen Biological Medical Science and Technology has completed its acquisition in its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH) on March 26. Jinhushen, on Dec 19, 2020, entered into a sale and purchase agreement (SPA) with Tianjin B...

FOLLOWING a transfer of a two-thirds ownership in Chinese conglomerate Tianjin Pharmaceutical Holdings (TPH) to a third party, a "chain offer" for the remaining shares of Tianjin Zhong Xin Pharmaceutical Group on both the Singapore and Shanghai bourses that are not held by offeror ...

Tianjin Zhong Xin Pharmaceutical Group announced on Dec 20 that Jinhushen Biological Medical Science and Technology has acquired a 67% stake in its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH). See: Tianjin Zhong Xin Pharmaceutical triggers SGX query as shares increase by over...

TIANJIN Zhong Xin Pharmaceutical Group announced on Sunday that Jinhushen Biological Medical Science and Technology will be acquiring a 67 per cent stake in its controlling shareholder Tianjin Pharmaceutical Holdings for an undisclosed sum.